| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0090-4295(96)00315-9 |
| P698 | PubMed publication ID | 8973674 |
| P2093 | author name string | G L Andriole | |
| D K Ornstein | |||
| B Johnson | |||
| G S Rao | |||
| E T Charlton | |||
| P2860 | cites work | The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group | Q33970656 |
| Leuprolide versus diethylstilbestrol for metastatic prostate cancer | Q34260348 | ||
| Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. | Q39481037 | ||
| Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma | Q40383481 | ||
| Finasteride | Q40384709 | ||
| Prostate cancer. Primary hormonal treatment | Q40873311 | ||
| Antiandrogenic agents as monotherapy in advanced prostatic carcinoma | Q40873337 | ||
| Sequential androgen blockade: a biological study in the inhibition of prostatic growth | Q41086635 | ||
| A controlled trial of leuprolide with and without flutamide in prostatic carcinoma | Q41261975 | ||
| Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer | Q44244189 | ||
| Patients' choice of treatment in stage D prostate cancer | Q44244446 | ||
| A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group | Q45081054 | ||
| Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues | Q48368446 | ||
| Treatment with finasteride following radical prostatectomy for prostate cancer | Q61703932 | ||
| The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer | Q67532207 | ||
| Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer | Q67543167 | ||
| Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer | Q67543692 | ||
| Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma | Q67545210 | ||
| Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma | Q69299236 | ||
| Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA | Q70659234 | ||
| Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects | Q71752137 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 901-905 | |
| P577 | publication date | 1996-12-01 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | Combined finasteride and flutamide therapy in men with advanced prostate cancer | |
| P478 | volume | 48 |
| Q80298197 | Advanced prostate cancer: an update |
| Q34335616 | Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy |
| Q33832646 | Antiandrogens in prostate cancer |
| Q35215084 | Biochemical recurrence of prostate cancer |
| Q77628643 | Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed |
| Q44660551 | Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy |
| Q34138857 | Developments in nonsteroidal antiandrogens targeting the androgen receptor |
| Q37217579 | Does the level of prostate cancer risk affect cancer prevention with finasteride? |
| Q41429551 | Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782 |
| Q33534842 | Evaluation and management of the man who has failed primary curative therapy for prostate cancer |
| Q80296310 | Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer |
| Q44499095 | Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up |
| Q40754266 | Flavonoids can block PSA production by breast and prostate cancer cell lines |
| Q37204444 | Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient |
| Q35640636 | Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer |
| Q44628088 | Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer |
| Q30310550 | Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy |
| Q37428189 | Novel hormonal approaches in prostate cancer |
| Q35036558 | PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium |
| Q34544845 | Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action |
| Q73575083 | Photochemistry and phototoxicity studies of flutamide, a phototoxic anti-cancer drug |
| Q91669817 | Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer |
| Q80075180 | Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer |
| Q36395149 | Rising prostate-specific antigen after primary prostate cancer therapy |
| Q35123293 | Selecting a secondary treatment |
| Q74029855 | Tamoxifen for flutamide/finasteride-induced gynecomastia |
| Q35211254 | The truth is out there: an overall perspective on androgen deprivation. |
| Q44655027 | The use of flutamide as a single antiandrogen treatment for hormone‐refractory prostate cancer |
| Q35211260 | Variables in predicting survival based on treating "PSA-only" relapse |
| Q34707817 | What does prostate-specific antigen recurrence mean? |
Search more.